A single-center retrospective study assessing the safety of yttrium-90 radioembolization in combination with checkpoint inhibitor immunotherapy in patients with Hepatocellular Carcinoma
Latest Information Update: 22 Sep 2020
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Yttrium-90 (Primary)
- Indications Cholangiocarcinoma; Liver cancer
- Focus Adverse reactions
- 22 Sep 2020 New trial record